Nanexa signs evaluation agreement with a large global pharmaceutical company
Nanexa AB (publ) today announced that the company has signed a Material Transfer and Feasibility Study Agreement with one of the largest global pharmaceutical companies for the evaluation of Nanexa's drug delivery system, PharmaShell®, in a depot formulation of a monoclonal antibody.
The study aims to develop a long-acting formulation of one of the pharmaceutical company’s monoclonal antibodies, utilizing the PharmaShell system.
"Adding this project to our portfolio of collaborative ventures is truly gratifying, especially as we leverage our PharmaShell system in the field of monoclonal antibodies, an area we believe holds immense potential. It's, of course, equally thrilling for Nanexa to initiate a collaboration with this large pharmaceutical company. We eagerly anticipate commencing our work shortly, with the objective of producing results that can serve as the foundation for a more comprehensive development program," said David Westberg, CEO of Nanexa.
The agreement regulates, among other things, details of what shall be investigated, clarification regarding patent rights, and a determined fee to Nanexa for this evaluation.
